Glaxo Group Limited

Micro Focus Lcc

Glaxosmithkline Intellectual Property Development Limited

Shanghai Jmt-bio Technology Co., Ltd.

Shanghai Annova Biotechnology Co., Ltd.

Kai Long

Zehong Wan

Xiaomin Zhang

Yingxia Sang

Jian Wang

Tao Li

Hong Xu

Xiang Gao

Qian Liu

Xiao Ding

Eric Steven Manas

Krista B Goodman

Luigi Piero Stasi

Colin Michael Edge

Yi Fan

Zhaolong Tong

Lingli Wu

Haihua Yu

Xiaobo Su

Ruixiang Chen

Sarah E Dowdell

Liping Song

Xiaotian Cui

Haixiang Wu

Jiana Jia

Ganliang Zhang

Yisha She

Jun-Chen Peng

Qiongfeng Xu

A substituted fused heterocyclic compound, and a preparation method therefor and the use thereof. Provided is a compound having the structure of formula I or a pharmaceutically acceptable salt thereof. The compound or the pharmaceutically acceptable salt thereof can be used as an ATR inhibitor, which has a high activity.

Substituted morpholines as ATR kinase inhibitors

Provided is a bispecific recombinant protein, comprising a high affinity tumor-targeting arm and a low affinity fusion protein blocking the interaction of CD47 with SIRP&#x3b1;. The antibody corresponding to the high affinity tumor-targeting arm does not bind to CD47, and its binding affinity to the target antigen on the tumor cell is at least 6 times as great as the binding affinity of monomer fusion protein homodimer corresponding to the low affinity fusion protein blocking the interaction of CD47 with SIRP&#x3b1;, to a CD47 on the tumor cell, wherein the low affinity fusion protein blocking the interaction of CD47 with SIRP&#x3b1; comprises a SIRP&#x3b1; extracellular truncation. Also provided are nucleic acid molecules encoding recombinant proteins and the use of the recombinant proteins and nucleic acid molecules in the manufacture of a medicament for treating tumors.

Bispecific recombinant protein and use thereof

A test script is divided into tests having a sequential order within the test script. An analysis tree of the tests can be generated. Each unique path through the analysis tree includes a subset of the tests as sequentially ordered within the test script. A maximally parallel subset of the unique paths that covers all the tests and according to which the tests are successfully executable is identified. Each test appears in only one unique path of the maximally parallel subset.

Maximally parallel test script execution

The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

Compounds

The present invention relates to novel compounds that inhibit Lp-PLAactivity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA, for example atherosclerosis, Alzheimer's disease.

[object Object]

Disclosed are 2,3-dihydroimiazo[1,2-c]pyrimidin-5(IH)-one compounds that inhibit Lp-PLA,processes for their preparation, compositions containing them and their use in the treatment of diseases associated with the activity of Lp-PLA, for example atherosclerosis, Alzheimer's disease.

2,3-dihydroimidazo[1, 2-c] pyrimidin-5(1 H)-one compounds use as LP-PLA2 inhibitors

The present invention relates to novel compounds that inhibit Lp-PLAactivity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.

Tricyclic compounds, preparation methods, and their uses

Growing community of inventors

Shanghai, China

Kai Long